Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Engaging community leaders to improve male partner participation in the prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania.

Lyatuu GW, Naburi H, Urrio R, Mwashemele SZ, Mdingi S, Panga R, Koda H, Chende Y, Tsere M, Mhalu A, Siril H, Lema IA, Aris E, Muya AN, Galanti MR, Biberfeld G, Kilewo C, Ekström AM.

PLoS One. 2018 Dec 12;13(12):e0207986. doi: 10.1371/journal.pone.0207986. eCollection 2018.

2.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

3.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Viegas EO, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O, Stout R, Scarlatti G, Ferrari G, Earl PL, Wahren B, Andersson S, Robb ML, Osman N, Biberfeld G, Jani I, Sandström E.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):193-205. doi: 10.1089/AID.2017.0121. Epub 2017 Nov 27.

4.

Job satisfaction and turnover intentions among health care staff providing services for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania.

Naburi H, Mujinja P, Kilewo C, Orsini N, Bärnighausen T, Manji K, Biberfeld G, Sando D, Geldsetzer P, Chalamila G, Ekström AM.

Hum Resour Health. 2017 Sep 6;15(1):61. doi: 10.1186/s12960-017-0235-y.

5.

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.

Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, Falkeborn T, Sharma S, Liakina V, Robb M, Eller M, Moss B, Biberfeld G, Sandström E, Nilsson C, Markland K, Blomberg P, Wahren B.

Heliyon. 2017 Jun 29;3(6):e00339. doi: 10.1016/j.heliyon.2017.e00339. eCollection 2017 Jun.

6.

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.

Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, Geldmacher C.

J Virol. 2017 Aug 24;91(18). pii: e00730-17. doi: 10.1128/JVI.00730-17. Print 2017 Sep 15.

7.

The potential of task-shifting in scaling up services for prevention of mother-to-child transmission of HIV: a time and motion study in Dar es Salaam, Tanzania.

Naburi H, Ekström AM, Mujinja P, Kilewo C, Manji K, Biberfeld G, Sando D, Chalamila G, Bärnighausen T.

Hum Resour Health. 2017 May 26;15(1):35. doi: 10.1186/s12960-017-0207-2.

8.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, Tecleab T, Liakina V, Scarlatti G, Robb ML, Earl PL, Moss B, Wahren B, Mhalu F, Ferrari G, Sandstrom E, Biberfeld G.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):880-888. doi: 10.1089/AID.2016.0251. Epub 2017 Jan 27.

9.

Predictors of Patient Dissatisfaction with Services for Prevention of Mother-To-Child Transmission of HIV in Dar es Salaam, Tanzania.

Naburi H, Mujinja P, Kilewo C, Bärnighausen T, Orsini N, Manji K, Biberfeld G, Sando D, Geldsetzer P, Chalamila G, Ekström AM.

PLoS One. 2016 Oct 21;11(10):e0165121. doi: 10.1371/journal.pone.0165121. eCollection 2016.

10.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S.

PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. eCollection 2016.

11.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

12.

Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.

Ngarina M, Kilewo C, Karlsson K, Aboud S, Karlsson A, Marrone G, Leyna G, Ekström AM, Biberfeld G.

BMC Infect Dis. 2015 Apr 8;15:175. doi: 10.1186/s12879-015-0914-z.

13.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.

14.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

15.

Incidence of HIV and the prevalence of HIV, hepatitis B and syphilis among youths in Maputo, Mozambique: a cohort study.

Viegas EO, Tembe N, Macovela E, Gonçalves E, Augusto O, Ismael N, Sitoe N, De Schacht C, Bhatt N, Meggi B, Araujo C, Sandström E, Biberfeld G, Nilsson C, Andersson S, Jani I, Osman N.

PLoS One. 2015 Mar 23;10(3):e0121452. doi: 10.1371/journal.pone.0121452. eCollection 2015.

16.

Women's preferences regarding infant or maternal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV during breastfeeding and their views on Option B+ in Dar es Salaam, Tanzania.

Ngarina M, Tarimo EA, Naburi H, Kilewo C, Mwanyika-Sando M, Chalamilla G, Biberfeld G, Ekstrom AM.

PLoS One. 2014 Jan 22;9(1):e85310. doi: 10.1371/journal.pone.0085310. eCollection 2014.

17.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

18.

Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania.

Ngarina M, Popenoe R, Kilewo C, Biberfeld G, Ekstrom AM.

BMC Public Health. 2013 May 7;13:450. doi: 10.1186/1471-2458-13-450.

19.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

20.

Treatment of Kaposi sarcoma in human immunodeficiency virus-1-infected Mozambican children with antiretroviral drugs and chemotherapy.

Vaz P, Macassa E, Jani I, Thome B, Mahagaja E, Madede T, Muando V, Biberfeld G, Anderson S, Blanche S.

Pediatr Infect Dis J. 2011 Oct;30(10):891-3. doi: 10.1097/INF.0b013e318228fb04.

PMID:
21730886
21.

Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, Montefiori DC, Otting N, Bontrop R, Bergmeier LA, Singh M, Wyatt RT, Schuitemaker H, Biberfeld G, Thorstensson R, Lehner T.

J Virol. 2011 Jul;85(13):6442-52. doi: 10.1128/JVI.00129-11. Epub 2011 Apr 13.

22.

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Bråve A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9. doi: 10.1016/j.vaccine.2010.08.108. Epub 2010 Oct 15.

PMID:
20951666
23.

High sexual risk taking and diverging trends of HIV-1 and HIV-2 in the military of Guinea Bissau.

Biague A, Månsson F, da Silva Z, Dias F, Nantote Q, Costa J, Andersson S, Nauclér A, Biberfeld G, Fenyö EM, Norrgren H.

J Infect Dev Ctries. 2010 Jun 3;4(5):301-8.

24.

Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.

Aboud S, Nilsson C, Karlén K, Marovich M, Wahren B, Sandström E, Gaines H, Biberfeld G, Godoy-Ramirez K.

Clin Vaccine Immunol. 2010 Jul;17(7):1124-31. doi: 10.1128/CVI.00008-10. Epub 2010 May 12.

25.

Nonvertical, nonsexual transmission of human immunodeficiency virus in children.

Vaz P, Pedro A, Le Bozec S, Macassa E, Salvador S, Biberfeld G, Blanche S, Andersson S.

Pediatr Infect Dis J. 2010 Mar;29(3):271-4. doi: 10.1097/INF.0b013e3181c17a58.

PMID:
20016396
26.

Comparison of the performance of rapid HIV tests using samples collected for surveillance in Mozambique.

Melo J, Nilsson C, Mondlane J, Osman N, Biberfeld G, Folgosa E, Andersson S.

J Med Virol. 2009 Dec;81(12):1991-8. doi: 10.1002/jmv.21633.

PMID:
19856475
27.

Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience.

Mugusi F, Mugusi S, Bakari M, Hejdemann B, Josiah R, Janabi M, Aboud S, Aris E, Swai H, Mhalu F, Biberfeld G, Pallangyo K, Sandstrom E.

Trop Med Int Health. 2009 Oct;14(10):1226-32. doi: 10.1111/j.1365-3156.2009.02359.x. Epub 2009 Sep 3.

28.

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.

Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, Lipyoga R, Mhalu F, Biberfeld G; Mitra Plus Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):406-16. doi: 10.1097/QAI.0b013e3181b323ff.

PMID:
19730269
29.

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B.

Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.

30.

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G; HIV Immunogenicity Study 01/02 Team.

J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507.

31.

Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study.

Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, Biberfeld G; Mitra Study Team.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):315-23. doi: 10.1097/QAI.0b013e31816e395c.

PMID:
18344879
32.

Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects.

Nilsson C, Aboud S, Karlén K, Hejdeman B, Urassa W, Biberfeld G.

Clin Vaccine Immunol. 2008 Apr;15(4):585-9. doi: 10.1128/CVI.00161-07. Epub 2008 Feb 20.

33.

Slow progression of HIV-1 infection in a cohort of antiretroviral naïve hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes.

Bakari M, Urassa W, Mhalu F, Biberfeld G, Pallangyo K, Sandström E.

Scand J Infect Dis. 2008;40(5):407-13.

PMID:
17943637
34.

Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999.

Månsson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, Fenyö EM, Norrgren H.

Sex Transm Infect. 2007 Oct;83(6):463-7. Epub 2007 Jul 4.

35.

A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, Biberfeld G, Earl P, Moss B, Cox JH, Wahren B.

Mol Ther. 2007 Sep;15(9):1724-33. Epub 2007 Jun 19.

36.

Evaluation of HIV antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV testing strategy in Dar es Salaam, Tanzania.

Aboud S, Urassa W, Lyamuya E, Mhalu F, Biberfeld G.

J Virol Methods. 2006 Aug;135(2):192-6. Epub 2006 May 2.

PMID:
16647764
37.

HIV-1 infection prevalence and incidence trends in areas of contrasting levels of infection in the Kagera region, Tanzania, 1987-2000.

Kwesigabo G, Killewo J, Urassa W, Lugalla J, Emmelin M, Mutembei A, Mhalu F, Biberfeld G, Wall S, Sandstrom A.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):585-91.

PMID:
16284536
38.

A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry.

Godoy-Ramirez K, Mäkitalo B, Thorstensson R, Sandström E, Biberfeld G, Gaines H.

Cytometry A. 2005 Dec;68(2):71-80.

39.

Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?

Leroy V, Sakarovitch C, Cortina-Borja M, McIntyre J, Coovadia H, Dabis F, Newell ML, Saba J, Gray G, Ndugwa Ch, Kilewo Ch, Massawe A, Kituuka P, Okong P, Grulich A, von Briesen H, Goudsmit J, Biberfeld G, Haverkamp G, Weverling GJ, Lange JM; Ghent Group on HIV in Women and Children.

AIDS. 2005 Nov 4;19(16):1865-75.

PMID:
16227795
40.

Mortality during the first 24 months after delivery in relation to CD4 T-lymphocyte levels and viral load in a cohort of breast-feeding HIV-1-infected women in Dar es Salaam, Tanzania.

Kilewo C, Karlsson K, Swai A, Massawe A, Lyamuya E, Mhalu F, Biberfeld G.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):598-602.

PMID:
15793372
41.

Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.

Andersson S, Larsen O, Da Silva Z, Linder H, Norrgren H, Dias F, Thorstensson R, Aaby P, Biberfeld G.

Clin Exp Immunol. 2005 Mar;139(3):483-9.

42.

Antigen-specific beta-chemokine production and CD8 T-cell noncytotoxic antiviral activity in HIV-2-infected individuals.

Ahmed RK, Norrgren H, da Silva Z, Blaxhult A, Fredriksson EL, Biberfeld G, Andersson S, Thorstensson R.

Scand J Immunol. 2005 Jan;61(1):63-71.

43.

Innate immunity in experimental SIV infection and vaccination.

Ahmed RK, Biberfeld G, Thorstensson R.

Mol Immunol. 2005 Feb;42(2):251-8. Review.

PMID:
15488612
44.

The natural course of disease following HIV-1 infection in dar es salaam, Tanzania: a study among hotel workers relating clinical events to CD4 T-lymphocyte counts.

Bakari M, Urassa W, Pallangyo K, Swai A, Mhalu F, Biberfeld G, Sandström E.

Scand J Infect Dis. 2004;36(6-7):466-73.

PMID:
15307570
45.

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

Mäkitalo B, Lundholm P, Hinkula J, Nilsson C, Karlén K, Mörner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R.

J Gen Virol. 2004 Aug;85(Pt 8):2407-19.

PMID:
15269383
46.

Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania.

Urassa W, Bakari M, Sandström E, Swai A, Pallangyo K, Mbena E, Mhalu F, Biberfeld G.

AIDS. 2004 Feb 20;18(3):433-8.

PMID:
15090795
47.

Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques.

Söderlund J, Nilsson C, Loré K, Castanos-Velez E, Ekman M, Heiden T, Biberfeld G, Andersson J, Biberfeld P.

J Med Primatol. 2004 Feb;33(1):16-24.

PMID:
15061728
48.

Estimation of CD4 T-lymphocyte counts from percent CD4 T-lymphocyte determinations in HIV-1-infected subjects in sub-Saharan Africa.

Sandström E, Urassa W, Bakari M, Swai A, Mhalu F, Biberfeld G, Pallangyo K.

Int J STD AIDS. 2003 Aug;14(8):547-51.

PMID:
12935385
49.

Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam.

Bakari M, Moshi A, Aris EA, Chale S, Josiah R, Magao P, Pallangyo N, Mugusi F, Sandström E, Biberfeld G, Mhalu F, Pallangyo K.

East Afr Med J. 2000 Sep;77(9):494-7.

PMID:
12862141
50.

Clinical progression in early and late stages of disease in a cohort of individuals infected with human immunodeficiency virus-2 in Guinea-Bissau.

Norrgren H, da Silva Z, Biague A, Andersson S, Biberfeld G.

Scand J Infect Dis. 2003;35(4):265-72.

PMID:
12839157

Supplemental Content

Loading ...
Support Center